Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 18;151(7):460-473.
doi: 10.1161/CIRCULATIONAHA.124.072418. Epub 2025 Feb 11.

Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study

Affiliations

Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study

Amy Johnston et al. Circulation. .

Abstract

Background: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as cardiovascular disease later in life. Despite the robust association between hypertension and atrial fibrillation (AFib), comparatively little is known about HDP and its subtypes as sex-specific risk factors for AFib.

Methods: A population-based retrospective cohort study was conducted, including 771 521 nulliparous women discharged for obstetrical delivery of their first live or stillborn singleton infant between 2002 and 2017 in Ontario, Canada. Data were obtained from record-level, coded, and linked population-based administrative databases housed at ICES. Using competing risks Cox proportional hazards regression, we estimated crude and multivariable-adjusted cause-specific hazard ratios and 95% CIs for associations between history of any HDP (and its 6 subtypes), and AFib before death, as well as all-cause mortality without a previous AFib diagnosis.

Results: Approximately 8% of women were diagnosed with HDP during the 16-year exposure accrual period. The total person-time of follow-up was 7 380 304 person-years, during which there were 2483 (0.3%) incident AFib diagnoses and 2951 (0.4%) deaths. History of any HDP was associated with an increased cause-specific hazard ratios of incident AFib and death without a previous AFib diagnosis (adjusted cause-specific hazard ratios, 1.45 [95% CI, 1.28-1.64] and 1.31 [95% CI, 1.16-1.47], respectively). These associations were observed in relatively young women (median time to event, 7 years postpartum). Associations suggestive of a dose-response relationship were observed, with more severe HDP subtypes and prepregnancy chronic hypertension associated with a 1.5 to 2.2 times higher cause-specific rate of AFib, and a 1.4 to 2.1 times higher cause-specific rate of death compared with no hypertension in pregnancy.

Conclusions: Women exposed to HDP in their first delivery have a significantly increased cause-specific hazard ratios of incident AFib compared to their unexposed counterparts, with higher rates observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic hypertension in pregnancy. These findings underscore the need to consider HDP history in risk calculation/stratification for arrhythmic and nonarrhythmic cardiovascular diseases, improve surveillance of traditional and female-specific cardiovascular disease risk factors, and develop targeted prevention strategies to reduce the occurrence and burden of HDP.

Keywords: atrial fibrillation; epidemiology; hypertension; preeclampsia; pregnancy; retrospective cohort.

PubMed Disclaimer

Conflict of interest statement

When this project was initiated, D.B.F. was employed by the University of Ottawa and had an academic appointment at the Children’s Hospital of Eastern Ontario Research Institute; although she continues to hold adjunct appointments in both institutions, she is now employed by Pfizer and works on an unrelated topic. The other authors report no conflicts.

Figures

Figure 1.
Figure 1.
Flow diagram illustrating the selection of study subjects.
Figure 2.
Figure 2.
Summary of the study methodology. AFib indicates atrial fibrillation; f/u, follow-up; GH, gestational hypertension; HDP, hypertensive disorders of pregnancy; HTN, hypertension; OSA, obstructive sleep apnea; and PCOS, polycystic ovarian syndrome.
Figure 3.
Figure 3.
Proportion of study subjects (per 1000 deliveries) diagnosed with a hypertensive disorder of pregnancy during the exposure accrual period of the study, by subtype. For each hypertensive disorders of pregnancy subtype, the numerator included the total number of subjects diagnosed with that specific subtype during the study period, and the denominator included the total number of study subjects.
Figure 4.
Figure 4.
Cause-specific cumulative incidence curves for atrial fibrillation (outcome) and all-cause mortality (competing risk) stratified by hypertensive disorder of pregnancy exposure status (first obstetrical delivery).
Figure 5.
Figure 5.
Case-specific adjusted hazard rations for atrial fibrillation and all-cause mortality. Cause-specific multivariable adjusted hazard ratios and accompanying 95% CIs (log-scale) for atrial fibrillation (A) and all-cause mortality (B) by any hypertensive disorder of pregnancy and each subtype. Hazard ratios adjusted for maternal age at delivery, diabetes, polycystic ovary syndrome, sleep apnea, smoking, kidney disease, obesity, chronic immune-mediated conditions, and Ontario Marginalization Index material resources dimension (quintiles).

References

    1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:416–441. doi: 10.1016/s1701-2163(15)30588-0 - PubMed
    1. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90:1499–1504. doi: 10.1136/hrt.2004.035444 - PMC - PubMed
    1. Anthony J, Damasceno A, Ojjii D. Hypertensive disorders of pregnancy: what the physician needs to know. Cardiovasc J Afr. 2016;27:104–110. doi: 10.5830/CVJA-2016-051 - PMC - PubMed
    1. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, Weissgerber TL, Milic N, Weaver A, Mielke MM. Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol. 2020;75:2323–2334. doi: 10.1016/j.jacc.2020.03.028 - PMC - PubMed
    1. Coutinho T, Lamai O, Nerenberg K. Hypertensive disorders of pregnancy and cardiovascular diseases: current knowledge and future directions. Curr Treat Options Cardiovasc Med. 2018;20:56. doi: 10.1007/s11936-018-0653-8 - PubMed